14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
A federal court in Nebraska recently rejected a health plan’s fiduciary breach claims under the Emp...
Read More >
Section 104(b)(4) of ERISA provides that a plan administrator must respond to a written request for ...
Read More >
In this episode of Trekking Through Compliance, we consider the episode The Doomsday Machine which a...
Read More >
“Unconscionability” is alive and well, as last week the California high Court renewed its 30-year ...
Read More >
On June 14, the Iowa Legislature passed HF2641 which consists of multiple amendments to Iowa tax law...
Read More >
Singapore analytics and acoustic solutions company H3 Zoom.AI’s founder, Shaun Koo, began using dro...
Read More >